Vaccine Development

Apr 01, 2007
BioPharm International
The Chinese vaccine market competition is now transferring from the former price-competition model to a technology- competition model.
Jul 01, 2006
BioPharm International
The approvals of two groundbreaking vaccines in the last month is encouraging news. Vaccines have long been undervalued because they haven't been as profitable as other pharmaceuticals. So it's good to see them getting deserved attention that goes beyond fears of flu outbreaks.
Jun 27, 2006
BioPharm Bulletin
The transdermal delivery of biologics-as well as of conventional drugs-is growing in popularity because the technique offers numerous advantages.
Jun 27, 2006
BioPharm International
By BioPharm International Editors
Several recent approvals highlight progress in developing both prophylactic and therapeutic vaccines.
Jun 01, 2006
BioPharm International
Disposables can be used for media preparation, clarification, filling in downstream processes . . .
May 01, 2006
BioPharm International
By BioPharm International Editors
The federal government plans to spend $3.3 billion on bird flu initiatives, about half of that on a vaccine.
May 01, 2006
BioPharm International
By BioPharm International Editors
Certain areas of the vaccine market appear to be in vogue again, revitalized by blockbusters such as Prevnar, the pneumococcal pneumonia vaccine that reaped $1.5 billion in sales last year, and the human papilloma virus vaccines, which are projected to reach $4 billion per year.
Feb 01, 2006
BioPharm International
Human infections with avian flu strain H5N1 are occurring in a number of southeast Asian countries that have experienced large outbreaks of avian influenza. How great a risk to the human population is posed by this virus, and what steps can be taken to minimize its impact? Preventive vaccines have great potential to avert the spread of avian flu and other infectious diseases. What are the factors affecting the creation of new vaccines, and how can they be optimized to promote public health?
Jul 01, 2005
BioPharm International
FDA plans to conduct good manufacturing practices (GMP) inspections of flu vaccine manufacturers annually instead of every two years.
Mar 01, 2005
BioPharm International
Bioterrorism legislation is in the works, but there will be a tough fight to enact added liability protections for manufacturers.
native1_300x100
lorem ipsum